|
1
|
Kris MG, Johnson BE, Berry LD, Kwiatkowski
DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson
SL, Su PF, et al: Using multiplexed assays of oncogenic drivers in
lung cancers to select targeted drugs. JAMA. 311:1998–2006. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grigoriu B, Berghmans T and Meert AP:
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Eur Respir J. 45:1132–1141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Inoue A, Kobayashi K, Usui K, Maemondo M,
Okinaga S, Mikami I, Ando M, Yamazaki K, Saijo Y, Gemma A, et al
North East Japan Gefitinib Study Group, : First-line gefitinib for
patients with advanced non-small-cell lung cancer harboring
epidermal growth factor receptor mutations without indication for
chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K,
Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, et al: The
International Association for the Study of Lung Cancer Consensus
Statement on Optimizing Management of EGFR Mutation-Positive
Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol.
11:946–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YJ, Kim HT, Han JY, Yun T, Lee GK, Kim
HY, Sung JH and Lee JS: First-line gefitinib treatment for patients
with advanced non-small cell lung cancer with poor performance
status. J Thorac Oncol. 5:361–368. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et
al: AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR
T790M-Positive Lung Cancer. N Engl J Med. (In press).
|
|
9
|
Hata A, Katakami N, Yoshioka H, Kaji R,
Masago K, Fujita S, Imai Y, Nishiyama A, Ishida T, Nishimura Y, et
al: Spatiotemporal T790M Heterogeneity in Individual Patients with
EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to
EGFR-TKI. J Thorac Oncol. 10:1553–1559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu
C, Zhang X, Zhao N, Su J, Yang J, et al: The role of T790M mutation
in EGFR-TKI re-challenge for patients with EGFR-mutant advanced
lung adenocarcinoma. Oncotarget. 8:4994–5002. 2017.PubMed/NCBI
|
|
11
|
Hata A, Katakami N, Yoshioka H, Takeshita
J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al:
Rebiopsy of non-small cell lung cancer patients with acquired
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitor: Comparison between T790M mutation-positive and
mutation-negative populations. Cancer. 119:4325–4332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Togashi Y, Masago K, Masuda S, Mizuno T,
Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, et al:
Cerebrospinal fluid concentration of gefitinib and erlotinib in
patients with non-small cell lung cancer. Cancer Chemother
Pharmacol. 70:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada
T, Mochizuki S, Okada Y, Nakada M, Murakami T and Yano S: High
efficacy of third generation EGFR inhibitor AZD9291 in a
leptomeningeal carcinomatosis model with EGFR-mutant lung cancer
cells. Oncotarget. 7:3847–3856. 2016.PubMed/NCBI
|
|
14
|
Ballard P, Yates JW, Yang Z, Kim DW, Yang
JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, et al:
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in
EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of
Clinical Brain Metastases Activity. Clin Cancer Res. 22:5130–5140.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pareek V, Welch M, Ravera E, Zampolin RL,
Sequist LV and Halmos B: Marked Differences in CNS Activity among
EGFR Inhibitors: Case Report and Mini-Review. J Thorac Oncol.
11:e135–e139. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Omuro AM, Kris MG, Miller VA, Franceschi
E, Shah N, Milton DT and Abrey LE: High incidence of disease
recurrence in the brain and leptomeninges in patients with nonsmall
cell lung carcinoma after response to gefitinib. Cancer.
103:2344–2348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin JJ, Cardarella S, Lydon CA, Dahlberg
SE, Jackman DM, Jänne PA and Johnson BE: Five-Year Survival in
EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
J Thorac Oncol. 11:556–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahama T, Sakai K, Takeda M, Azuma K,
Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, et al:
Detection of the T790M mutation of EGFR in plasma of advanced
non-small cell lung cancer patients with acquired resistance to
tyrosine kinase inhibitors (West Japan oncology group 8014LTR
study). Oncotarget. 7:58492–58499. 2016.PubMed/NCBI
|
